Free Cash Flow (Quarterly) Chart

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
September 30, 2026 -6.114M
June 30, 2026 -20.92M
March 31, 2026 -19.44M
December 31, 2025 -17.99M
September 30, 2025 -19.82M
June 30, 2025 -5.926M
March 31, 2025 -35.28M
December 31, 2024 -0.4617M
September 30, 2024 -23.91M
June 30, 2024 -30.17M
March 31, 2024 -5.797M
December 31, 2023 -1.382M
September 30, 2023 -32.55M
June 30, 2023 50.23M
March 31, 2023 -36.56M
December 31, 2022 151.53M
September 30, 2022 -42.55M
June 30, 2022 -34.47M
March 31, 2022 -51.15M
December 31, 2021 -46.33M
September 30, 2021 -18.91M
June 30, 2021 -33.48M
March 31, 2021 -43.07M
December 31, 2020 -8.128M
September 30, 2020 -16.98M
Date Value
June 30, 2020 -8.925M
March 31, 2020 -12.00M
December 31, 2019 -8.012M
September 30, 2019 -3.006M
June 30, 2019 9.098M
March 31, 2019 -5.489M
December 31, 2018 -5.692M
September 30, 2018 -6.840M
June 30, 2018 -8.331M
March 31, 2018 -0.723M
December 31, 2017 9.854M
September 30, 2017 -1.401M
June 30, 2017 -4.217M
March 31, 2017 -4.965M
December 31, 2016 -3.942M
September 30, 2016 -6.741M
June 30, 2016 -4.210M
March 31, 2016 -4.46M
December 31, 2015 -4.245M
September 30, 2015 -5.515M
June 30, 2015 -4.000M
March 31, 2015 -4.607M
December 31, 2014 -6.014M
September 30, 2014 -9.307M
June 30, 2014 -5.539M

Free Cash Flow Definition

Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 10.26M
Emergent BioSolutions, Inc. 96.80M
Ionis Pharmaceuticals, Inc. -193.63M
United Therapeutics Corp. 125.80M
Ocugen, Inc. -15.89M